EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.58), $0.04 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $9.48 million versus the consensus estimate of $9.64 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• SpaceX (SPCX) call put ratio 1 calls to 1.1 puts as share price at $155
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth